Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

Claims 1- 32 (Canceled)

33. (Currently Amended) A method of formulating a therapeutic liposome composition having sensitivity to a target cell, comprising

~~selecting~~ providing a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent;

~~selecting from~~ providing a plurality of targeting conjugates a targeting conjugate composed of (i) a lipid having a polar head group and a hydrophobic tail, (ii) a hydrophilic polymer having a proximal end and a distal end, said polymer attached at its proximal end to the head group of the lipid, and (iii) a targeting ligand attached to the distal end of the polymer; and

combining the ~~selected~~ liposome formulation and the ~~selected~~ plurality of targeting conjugates to form said therapeutic, target-cell sensitive liposome composition.

34. (Currently Amended) The method of claim 33, wherein said combining includes incubating under conditions effective to achieve insertion of ~~the selected~~ said targeting conjugates into ~~the~~ said pre-formed liposomes ~~of the selected liposome formulation~~.

35. (Canceled)

36. (Currently Amended) The method of claim 33, wherein said ~~selecting~~ providing a plurality of targeting conjugates includes providing a plurality of targeting conjugates having a ~~determining the ability of the~~ targeting ligand effective to bind cell surface receptors expressed on ~~the~~ a target cell.

37. (Currently Amended) The method of claim 36, wherein said ~~selecting~~ providing a plurality of targeting conjugates includes providing a plurality of targeting conjugates

having a targeting ligand with binding affinity for a cell receptor, where binding of said ligand with said cell receptor results in internalization of said liposomes ~~is based on (i) the ability of a targeting ligand to bind to cell surface receptors expressed on the target cell and (ii) the ability of the target cell to internalize liposomes bound to the target cell by binding between the target cell and the targeting ligand~~.

38. (Original) The method of claim 33, wherein the targeting ligand is an antibody or an antibody fragment.

39. (Currently Amended) The method of claim 38, wherein the antibody or antibody fragment is ~~of mouse origin and is~~ a humanized ~~to remove~~ murine antibody ~~epitopes~~.

40. (Original) The method of claim 38, wherein the targeting ligand specifically binds to an extracellular domain of a growth factor receptor.

41. (Original) The method of claim 40, wherein the receptors are selected from the group consisting of c-erbB-2 protein product of the HER2/neu oncogene, epidermal growth factor receptor, basic fibroblast growth factor receptor, and vascular endothelial growth factor receptor.

42. (Original) The method of claim 38, wherein the targeting ligand binds a receptor selected from the group consisting of E-selectin receptor, L-selectin receptor, P-selectin receptor, folate receptor, CD4 receptor, CD19 receptor, $_{\alpha\beta}$ integrin receptors and chemokine receptors.

43. (Original) The method of claim 33, wherein the targeting ligand binds a receptor on a malignant B-cell or T-cell, said receptor selected from the group consisting of CD19, CD20, CD22, CD4, CD7 and CD8.

44. (Original) The method of claim 33, wherein the targeting ligand is selected from the group consisting of folic acid, pyridoxal phosphate, vitamin B12, sialyl Lewis^x,

transferrin, epidermal growth factor, basic fibroblast growth factor, vascular endothelial growth factor, VCAM-1, ICAM-1, PECAM-1, RGD peptides and NGR peptides.

45. (Original) The method of claim 33, wherein the hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol, polyaspartamide and hydrophilic peptide sequences.

46. (Original) The method of claim 33, wherein the hydrophilic polymer is polyethylene glycol.

47. (Original) The method of claim 46, wherein the polyethylene glycol has a molecular weight between 500-5,000 daltons.

48. (Original) The method of claim 33, wherein the liposomes further contain a cationic lipid.

49. (Original) The method of claim 33, wherein the entrapped therapeutic agent is a cytotoxic drug.

50. (Original) The method of claim 49 wherein the cytotoxic drug is an anthracycline antibiotic selected from the group consisting of doxorubicin, daunorubicin, epirubicin and idarubicin and analogs thereof.

51. (Original) The method of claim 49, wherein the cytotoxic agent is a platinum compound selected from cisplatin, carboplatin, ormaplatin, oxaliplatin, zeniplatin, enloplatin, lobaplatin, spiroplatin, ((-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutane dicarboxylato)platinum), (SP-4-3(R)-1,1-cyclobutane-dicarboxylato(2-)-(2-methyl-1,4-

butanediamine-N,N')platinum), nedaplatin and (bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV)).

52. (Original) The method of claim 49, wherein the cytotoxic agent is a topoisomerase 1 inhibitor selected from the group consisting of topotecan, irinotecan, (7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(S)-camptothecin), 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin, 9-aminocamptothecin and 9-nitrocamptothecin.

53. (Original) The method of claim 49, wherein the cytotoxic agent is a vinca alkaloid selected from the group consisting of vincristine, vinblastine, vinleurosine, vinrodisine, vinorelbine and vindesine.

54. (Original) The method of claim 33, wherein the entrapped agent is a nucleic acid.

55. (Original) The method of claim 54, wherein the nucleic acid is an antisense oligonucleotide or ribozyme.

56. (Original) The method of claim 54, wherein the nucleic acid is a plasmid containing a therapeutic gene which when internalized by the target cells achieves expression of the therapeutic gene to produce a therapeutic gene product.

57. (New) The method of claim 32, wherein said providing a liposomal composition comprises providing a liposomal composition composed of pre-formed liposomes having entrapped doxorubicin.

58. (New) The method of claim 32, wherein said providing a plurality of targeting conjugates comprises providing a plurality of targeting conjugates comprised of a vesicle-forming lipid, polyethylene glycol, and a targeting ligand having binding affinity for a cell receptor.